Source: Annual Congress 2013 –Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Cherenko, N. Kibiziva, M. Pogrebnaya, J. Senko (Kiev, Ukraine). Linezolid in the treatment of patients with MDR TB and XDR TB. Eur Respir J 2013; 42: Suppl. 57, 2818

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Why did they get XDR TB ? Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005